Robert Grant, MD, MPH

Professor

Dr. Grant believes that clinical and public health practice inspires the best research. His goal is to find ways for people to breath more easily, and to end HIV transmission and disease. His work with HIV started in 1983 with the epidemic when he was a graduate student in epidemiology at UC Berkeley. With the completion of his work pioneering HIV pre-exposure prophylaxis (or PrEP) in 2014, he pivoted to focus on the underpinnings of the epidemic, including stigma, trauma, injustice, addiction, and depression. His current clinical practice is on pulmonary medicine, and how breathing intersects with emotional well being. The next phase of his research focuses on novel transformative interventions for depression and anxiety, including ketamine and MDMA assisted psychotherapies.

Dr. Grant has had a clinical practice in pulmonary and critical care medicine from 1994 to the present, including at Zuckerberg San Francisco General Hospital, San Francisco Veterans Administration Medical Center, and UCSF Health. He started the Sexual Health Improvement Project at UCSF in 2014; this was the first clinical service at UCSF to offer HIV preexposure prophylaxis. He served as the Chief Medical Officer of the San Francisco AIDS Foundation from 2014 to 2018, where he oversaw the initiation of the largest PrEP service in San Francisco, HIV treatment initiation in a sexual health clinic, and HCV treatment linked with a needle exchange site. The SFAF PrEP service is innovative in being rooted in a community based organization, led by nurses, pioneering same day PrEP initiation (and later, same-day HIV treatment initiation), and offering education for non-daily or 2-1-1 PrEP dosing.

Dr. Grant has served as an advisor for laboratory medicine, antiretroviral therapy, and pre-exposure prophylaxis to the CDC, the FDA, and the WHO. He helped develop the WHO recommendation for PrEP (AIDS 2016) and he drafted the WHO PrEP Implementation Tool Kit in consultation with hundreds of experts and stakeholders around the world (https://www.who.int/hiv/pub/prep/prep-implementation-tool/en/). He co-founded a ketamine assisted psychotherapy practice called "Healing Realms" in 2017, and now serves on the board of directors of the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP). He is a mentor in the California Institute of Integral Studies Certificate Program in Psychedelic Treatment and Research (CIIS CPTR).

Key findings from Dr. Grant's research include the following:

1. Conceptualization and estimation of transmissibility: Dr. Grant developed the concept of transmissibility (now denoted with "beta") and developed a method for estimating transmission of HIV per sexual contact and per sexual partner using epidemiological data (JID 1987). This parameter formed the basis of a generation of mathematical models of infectious epidemics.

2. Diagnostic innovations that guide therapy: Dr. Grant was the first to demonstrate that oral fluid could be used for HIV diagnostic antibody testing (CDLI 1996). He later conducted research that led to the first sequence based assay for drug resistance (or any other condition) to be approved by the FDA (J Clin Micro 2003).

3. High viral load in nonpathogenic SIV infections: Dr. Grant's laboratory discovered a null allele of CCR5 in the natural host of simian immunodeficiency virus. The host genotype was associated with viral load in nonpathogenic infection (Current Biology 1998).

4. Drug resistant HIV has diminished clinical consequences: First case report of transmission of protease inhibitor resistant HIV-1 (NEJM 1998). Finding that primary drug resistance to certain classes of antiretroviral therapy is increasing overtime, and is associated with delayed virological responses to therapy (JAMA 2002). Finding that drug resistant viremia is associated with preserved CD4+ T cell count responses to therapy, suggesting a trade-off for the virus between resistance and virulence (AIDS 1999). Persistent partial CD4+ T cell count responses proved to require continued exposure to therapy that retains partial antiviral activity and maintains selection for viruses with diminished replication capacity (NEJM 2001).

5. Pre-exposure Prophylaxis is safe, effective, and feasible: Dr. Grant's iPrEx trial found that daily oral emtricitabine/tenofovir disoproxil fumarate decreases HIV acquisition among men who have sex with men and transgender women (NEJM 2010). He also conducted the first open label demonstration project of preexposure prophylaxis, showing that adherence is higher when information about safety and efficacy is provided (Lancet ID 2014). He published the first and still largest series of PrEP use among transgender women (Deutsch 2015). He and his colleagues Identified a correlate of protection and a candidate surrogate marker for efficacy of pre-exposure prophylaxis (Anderson 2012).

Education
Certificate, 2016 - Psychedelic Treatment and Research, California Institute of Integral Studies
Fellowship, 1996 - Pulmonary Medicine, University of California, San Francisco
Residency, 1991 - School of Medicine, University of California, San Francisco
M.D., 1988 - Medicine, University of California, San Francisco
M.P.H, 1986 - Epidemiology, University of California, Berkeley
M.H.S., 1986 - Health and Medical Sciences, University of California, Berkeley
B.S., A.B, 1983 - Biology, Latin American Studies, Stanford University
Honors and Awards
  • 150 Pioneers and Leaders in the AIDS Response, IAPAC, 2017
  • Association of American Physicians, 2012
  • 100 most influencial persons, Time Magazine, 2012
  • Leadership Award, San Francisco AIDS Foundation, 2011
  • People Who Mattered, Time Magazine, 2011
  • American Society Clinical Investigation, 2003
  • Alpha Omega Alpha, UCSF, 1988
  • Phi Beta Kappa, Stanford, 1983
Publications

  1. Avelino-Silva VI, Stone M, Bakkour S, Di Germanio C, Schmidt M, Conway AL, Wright D, Grebe E, Custer B, Kleinman SH, Deng X, Lingappa JR, Defechereux P, Mehrotra M, Grant RM, Vasan S, Facente S, Phanuphak N, Sacdalan C, Akapirat S, de Souza M, Busch MP, Norris PJ, NHLBI Recipient Epidemiology and Donor Evaluation Study-IV-Pediatric (REDS-IV-P). Suppressed HIV antibody responses following exposure to antiretrovirals - evidence from PrEP randomized trials and early antiretroviral treatment initiation studies. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2024. PMID: 39186969


  2. Wohl DA, Spinner CD, Flamm J, Hare CB, Doblecki-Lewis S, Ruane PJ, Molina JM, Mills A, Brinson C, Ramgopal M, Clarke A, Crofoot G, Martorell C, Carter C, Cox S, Hojilla JC, Shao Y, Das M, Kintu A, Baeten JM, Grant RM, Mounzer K, Mayer K. HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial. The lancet. HIV 2024. PMID: 39008999


  3. Landovitz RJ, Tao L, Yang J, de Boer M, Carter C, Das M, Baeten JM, Liu A, Hoover KW, Celum C, Grinsztejn B, Morris S, Wheeler DP, Mayer KH, Golub SA, Bekker LG, Diabaté S, Hoornenborg E, Myers J, Leech AA, McCormack S, Chan PA, Sweat M, Matthews LT, Grant R, Global F/TDF PrEP Study Team. HIV-1 Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-Exposure Prophylaxis: Pooled Analysis From 72 Global Studies. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2024. PMID: 38484128


  4. Garcia-Cremades M, Vucicevic K, Hendrix CW, Jayachandran P, Jarlsberg L, Grant R, Celum CL, Martin M, Baeten JM, Marrazzo J, Anderson P, Choopanya K, Vanichseni S, Glidden DV, Savic RM. Characterizing HIV-preventive, plasma tenofovir concentrations. A pooled participant-level data analysis from HIV pre-exposure prophylaxis (PrEP) clinical trials. 2022. PMID: 35474481


  5. Garcia-Cremades M, Hendrix CW, Jayachandran P, Strydom N, Jarlsberg L, Grant R, Celum CL, Martin M, Baeten JM, Marrazzo J, Anderson P, Choopanya K, Vanichseni S, Glidden DV, Savic RM. Modeling the Probability of HIV Infection over Time in High-Risk Seronegative Participants Receiving Placebo in Five Randomized Double-Blind Placebo-Controlled HIV Pre-Exposure Prophylaxis Trials: A Patient-Level Pooled Analysis. Pharmaceutics 2022. PMID: 36145549


  6. Sevelius JM, Glidden DV, Deutsch M, Welborn L, Contreras A, Salinas A, Venegas L, Grant RM. Uptake, Retention, and Adherence to Pre-exposure Prophylaxis (PrEP) in TRIUMPH: A Peer-Led PrEP Demonstration Project for Transgender Communities in Oakland and Sacramento, California. 2021. PMID: 34757990


  7. Grant RM, Pellegrini M, Defechereux PA, Anderson PL, Yu M, Glidden DV, O'Neal J, Yager J, Bhasin S, Sevelius J, Deutsch MB. Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the iBrEATHe Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020. PMID: 32766890


  8. Hughes SD, Koester KA, Engesaeth E, Hawkins MV, Grant RM. Human Enough: A Qualitative Study of Client Experience With Internet-Based Access to Pre-exposure Prophylaxis. Journal of medical Internet research 2021. PMID: 36256828


  9. Ibrahim ME, Glidden DV, Grant RM, Anderson PL. Letter to the Editor: Revisiting the Pharmacological Forgiveness of HIV Pre-Exposure Prophylaxis. AIDS research and human retroviruses 2021. PMID: 33913746


  10. Spinelli MA, Lowery B, Shuford JA, Spindler J, Kearney MF, McFarlane JR, McDonald C, Okochi H, Phung N, Kuncze K, Jee K, Johannessen D, Anderson PL, Smith DK, Defechereux P, Grant RM, Gandhi M. Use of Drug-Level Testing and Single-Genome Sequencing to Unravel a Case of HIV Seroconversion on PrEP. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020. PMID: 32686825


  11. Truong HM, Mehrotra ML, Grant RM, iPrEx Study Team. Brief Report: Seroadaptive Behaviors Varied Among Geographically Diverse iPrEx Participants. Journal of acquired immune deficiency syndromes (1999) 2021. PMID: 33093331


  12. O'Keefe KJ, Pipkin S, Fatch R, Scheer S, Liegler T, McFarland W, Grant RM, Truong HM. Non-B variants of HIV-1 in San Francisco, California. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 2020. PMID: 33321227


  13. Mayer KH, Molina JM, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, DeJesus E, Jessen H, Grant RM, Ruane PJ, Wong P, Ebrahimi R, Zhong L, Mathias A, Callebaut C, Collins SE, Das M, McCallister S, Brainard DM, Brinson C, Clarke A, Coll P, Post FA, Hare CB. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet (London, England) 2020. PMID: 32711800


  14. Dimitrov D, Moore JR, Wood D, Mitchell KM, Li M, Hughes JP, Donnell DJ, Mannheimer S, Holtz TH, Grant RM, Boily MC. Predicted effectiveness of daily and non-daily PrEP for MSM based on sex and pill-taking patterns from HPTN 067/ADAPT. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2019. PMID: 31437276


  15. Velloza J, Heffron R, Amico KR, Rowhani-Rahbar A, Hughes JP, Li M, Dye BJ, Celum C, Bekker LG, Grant RM. The Effect of Depression on Adherence to HIV Pre-exposure Prophylaxis Among High-Risk South African Women in HPTN 067/ADAPT. AIDS and behavior 2020. PMID: 31955360


  16. Spinelli MA, Rodrigues WC, Wang G, Vincent M, Glidden DV, Okochi H, Stalter R, Defechereux P, Deutsch M, Grant RM, Ngure K, Mugo NR, Baeten JM, Gandhi M. HIGH ACCURACY OF A REAL-TIME URINE ANTIBODY-BASED TENOFOVIR POINT-OF-CARE TEST COMPARED TO LABORATORY-BASED ELISA IN DIVERSE POPULATIONS. Journal of acquired immune deficiency syndromes (1999) 2020. PMID: 32167963


  17. Ascher SB, Scherzer R, Estrella MM, Shigenaga J, Spaulding KA, Glidden DV, Mehrotra ML, Defechereux P, Gandhi M, Grant RM, Shlipak MG, Jotwani V. HIV pre-exposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health. AIDS (London, England) 2019. PMID: 31794523


  18. Lopez MI, Grant RM, Dong BJ. Community pharmacy delivered PrEP to STOP HIV transmission: An opportunity NOT to miss! Journal of the American Pharmacists Association : JAPhA 2020. PMID: 32165026


  19. Koester KA, Hughes SD, Grant RM. "A Good Habit": Telehealth PrEP Users Find Benefit in Quarterly Monitoring Requirements. Journal of the International Association of Providers of AIDS Care 2020. PMID: 32323593


  20. Dong BJ, Lopez MI, Grant RM. Response to: Acceptability and Feasibility of a Pharmacist-Led HIV Pre-exposure Prophylaxis Program in the Midwestern United States. Open forum infectious diseases 2019. PMID: 31824977


  21. Holtz TH, Chitwarakorn A, Hughes JP, Curlin ME, Varangrat A, Li M, Amico KR, Mock PA, Grant RM. HPTN 067/ADAPT: Correlates of Sex-Related Pre-exposure Prophylaxis Adherence, Thai Men Who Have Sex With Men, and Transgender Women, 2012-2013. Journal of acquired immune deficiency syndromes (1999) 2019. PMID: 31490342


  22. Velloza J, Bacchetti P, Hendrix CW, Murnane P, Hughes JP, Li M, Curlin M, Holtz TH, Mannheimer S, Marzinke MA, Amico KR, Liu A, Piwowar-Manning E, Eshleman SH, Dye BJ, Gandhi M, Grant RM. Short and long-term pharmacologic measures of HIV pre-exposure prophylaxis use among high-risk men who have sex with men in HPTN 067/ADAPT. Journal of acquired immune deficiency syndromes (1999) 2019. PMID: 31335588


  23. Ojeda VD, Amico KR, Hughes JP, Wilson E, Li M, Holtz TH, Chitwarakorn A, Grant RM, Dye BJ, Bekker LG, Mannheimer S, Marzinke M, Hendrix CW. Low Disclosure of PrEP Nonadherence and HIV-Risk Behaviors Associated With Poor HIV PrEP Adherence in the HPTN 067/ADAPT Study. Journal of acquired immune deficiency syndromes (1999) 2019. PMID: 31169769


  24. Janet J M, Mi-Suk KD, Kimberly A K, Ifeoma U, Remi F, Rebecca P, Kristin K, Xavier E, Horowitz J, Robert G, Jeffrey H B. Adherence to PrEP among young men who have sex with men participating in a sexual health services demonstration project in Alameda County, California. Journal of acquired immune deficiency syndromes (1999) 2019. PMID: 30973542


  25. Mehrotra ML, Westreich D, McMahan VM, Glymour MM, Geng E, Grant RM, Glidden DV. Baseline Characteristics Explain Differences in Effectiveness of Randomization to Daily Oral TDF/FTC PrEP Between Transgender Women and Cisgender Men Who Have Sex With Men in the iPrEx Trial. Journal of acquired immune deficiency syndromes (1999) 2019. PMID: 31192894


  26. Spinelli MA, Glidden DV, Anderson PL, Gandhi M, McMahan VM, Defechereux P, Schechter M, Veloso VG, Chariyalertsak S, Guanira JV, Bekker LG, Buchbinder S, Grant RM. Impact of Estimated PrEP Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project. AIDS research and human retroviruses 2019. PMID: 31119944


  27. Chemnasiri T, Varangrat A, Amico KR, Chitwarakorn A, Dye BJ, Grant RM, Holtz TH. Facilitators and barriers affecting PrEP adherence among Thai men who have sex with men (MSM) in the HPTN 067/ADAPT Study. AIDS care 2019. PMID: 31159584


  28. Hojilla JC, Satre DD, Glidden DV, McMahan VM, Gandhi M, Defechereux P, Guanira JV, Mehrotra M, Grant RM, Carrico AW. Brief Report: Cocaine Use and Pre-exposure Prophylaxis: Adherence, Care Engagement, and Kidney Function. Journal of acquired immune deficiency syndromes (1999) 2019. PMID: 30730359


  29. Mannheimer S, Hirsch-Moverman Y, Franks J, Loquere A, Hughes JP, Li M, Amico KR, Grant RM. Factors Associated With Sex-Related Pre-exposure Prophylaxis Adherence Among Men Who Have Sex With Men in New York City in HPTN 067. Journal of acquired immune deficiency syndromes (1999) 2019. PMID: 30865051


  30. Spinelli MA, Glidden DV, Rodrigues WC, Wang G, Vincent M, Okochi H, Kuncze K, Mehrotra M, Defechereux P, Buchbinder SP, Grant RM, Gandhi M. Low tenofovir level in urine by a novel immunoassay is associated with seroconversion in a preexposure prophylaxis demonstration project. AIDS (London, England) 2019. PMID: 30649051


  31. Truong HM, Pipkin S, Grant RM, Liegler T, O'Keefe KJ, Scheer S. Increased uptake of early initiation of antiretroviral therapy and baseline drug resistance testing in San Francisco between 2001 and 2015. PloS one 2019. PMID: 30870438


  32. Cohen SE, Sachdev D, Lee SA, Scheer S, Bacon O, Chen MJ, Okochi H, Anderson PL, Kearney MF, Coffey S, Scott H, Grant RM, Havlir D, Gandhi M. Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report. The lancet. HIV 2018. PMID: 30503324


  33. Murray MI, Markowitz M, Frank I, Grant RM, Mayer KH, Hudson KJ, Stancil BS, Ford SL, Patel P, Rinehart AR, Spreen WR, Margolis DA. Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial. HIV clinical trials 2018. PMID: 30445896


  34. Mehrotra ML, Rivet Amico K, McMahan V, Glidden DV, Defechereux P, Guanira JV, Grant RM. The Role of Social Relationships in PrEP Uptake and Use Among Transgender Women and Men Who Have Sex with Men. AIDS and behavior 2018. PMID: 29754268


  35. Stekler JD, Violette LR, Niemann L, McMahan VM, Katz DA, Baeten JM, Grant RM, Delaney KP. Repeated False-Positive HIV Test Results in a Patient Taking HIV Pre-Exposure Prophylaxis. Open forum infectious diseases 2018. PMID: 30276221


  36. Koester KA, Erguera XA, Kang Dufour MS, Udoh I, Burack JH, Grant RM, Myers JJ. "Losing the Phobia:" Understanding How HIV Pre-exposure Prophylaxis Facilitates Bridging the Serodivide Among Men Who Have Sex With Men. Frontiers in public health 2018. PMID: 30238001


  37. Colby DJ, Kroon E, Sacdalan C, Gandhi M, Grant RM, Phanuphak P, Ananworanich J, Robb ML, Phanuphak N. Acquisition of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Infection in a Patient Taking Preexposure Prophylaxis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2018. PMID: 29961859


  38. Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM. Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2018. PMID: 29415175


  39. Truong HM, Fatch R, Grant RM, Mathur M, Kumta S, Jerajani H, Kellogg TA, Lindan CP. Characterization of HIV Recent Infection Among High-Risk Men at Public STI Clinics in Mumbai. AIDS and behavior 2018. PMID: 29453551


  40. Jotwani V, Scherzer R, Glidden DV, Mehrotra M, Defechereux P, Liu A, Gandhi M, Bennett M, Coca SG, Parikh CR, Grant RM, Shlipak MG. Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals. Journal of acquired immune deficiency syndromes (1999) 2018. PMID: 29767638


  41. Ryan KE, Mak A, Stoove M, Price B, Fairley CK, Ruth S, Lal L, Asselin J, El-Hayek C, Nguyen L, Batrouney C, Wilson D, Lockwood J, Murphy D, Cornelisse VJ, Roth N, Willcox J, Chang CC, Armishaw J, Tee BK, Penn M, Forgan-Smith G, Williams C, Montgomery J, Byron K, Coelho A, Allen B, Wiggins J, Kelsall J, Vujovic O, West M, Pierce AB, Gallant D, Bell C, de Wit JBF, Hoy JF, Wesselingh SL, Grant RM, Wright EJ. Protocol for an HIV Pre-exposure Prophylaxis (PrEP) Population Level Intervention Study in Victoria Australia: The PrEPX Study. Frontiers in public health 2018. PMID: 29896468


  42. Grant RM, Mannheimer S, Hughes JP, Hirsch-Moverman Y, Loquere A, Chitwarakorn A, Curlin ME, Li M, Amico KR, Hendrix CW, Anderson PL, Dye BJ, Marzinke MA, Piwowar-Manning E, McKinstry L, Elharrar V, Stirratt M, Rooney JF, Eshleman SH, McNicholl JM, van Griensven F, Holtz TH. Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2018. PMID: 29420695


  43. Davis AK, Barsuglia JP, Lancelotta R, Grant RM, Renn E. The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption. Journal of psychopharmacology (Oxford, England) 2018. PMID: 29708042


  44. Figueroa DB, Tillotson J, Li M, Piwowar-Manning E, Hendrix CW, Holtz TH, Bokoch K, Bekker LG, van Griensven F, Mannheimer S, Hughes JP, Grant RM, Bumpus NN. Discovery of genetic variants of the kinases that activate tenofovir among individuals in the United States, Thailand, and South Africa: HPTN067. PloS one 2018. PMID: 29641561


  45. Franks J, Hirsch-Moverman Y, Loquere AS, Amico KR, Grant RM, Dye BJ, Rivera Y, Gamboa R, Mannheimer SB. Sex, PrEP, and Stigma: Experiences with HIV Pre-exposure Prophylaxis Among New York City MSM Participating in the HPTN 067/ADAPT Study. AIDS and behavior 2018. PMID: 29143163


  46. Mitchell KM, Dimitrov D, Hughes JP, Xia F, Donnell D, Amico KR, Bokoch K, Chitwarakorn A, Bekker LG, Holtz TH, Mannheimer S, Grant RM, Boily MC. In what circumstances could nondaily preexposure prophylaxis for HIV substantially reduce program costs? AIDS (London, England) 2018. PMID: 29424774


  47. Fuchs JD, Stojanovski K, Vittinghoff E, McMahan VM, Hosek SG, Amico KR, Kouyate A, Gilmore HJ, Buchbinder SP, Lester RT, Grant RM, Liu AY. A Mobile Health Strategy to Support Adherence to Antiretroviral Preexposure Prophylaxis. AIDS patient care and STDs 2018. PMID: 29565183


  48. Hojilla JC, Vlahov D, Glidden DV, Amico KR, Mehrotra M, Hance R, Grant RM, Carrico AW. Skating on thin ice: stimulant use and sub-optimal adherence to HIV pre-exposure prophylaxis. Journal of the International AIDS Society 2018. PMID: 29577616


  49. Eshleman SH, Piwowar-Manning E, Sivay MV, Debevec B, Veater S, McKinstry L, Bekker LG, Mannheimer S, Grant RM, Chesney MA, Coates TJ, Koblin BA, Fogel JM. Performance of the BioPlex 2200 HIV Ag-Ab assay for identifying acute HIV infection. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2018. PMID: 29346085


  50. Baxi SM, Vittinghoff E, Bacchetti P, Huang Y, Chillag K, Wiegand R, Anderson PL, Grant R, Greenblatt RM, Buchbinder S, Gandhi M, Liu AY. Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial. PloS one 2018. PMID: 29315307


  51. Markowitz M, Grossman H, Anderson PL, Grant R, Gandhi M, Horng H, Mohri H. Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis. Journal of acquired immune deficiency syndromes (1999) 2017. PMID: 29076941


  52. Hojilla JC, Mehrotra M, Truong HM, Glidden DV, Amico KR, McMahan V, Vlahov D, Chariyalertsak S, Guanira JV, Grant RM. HIV sero disclosure among men who have sex with men and transgender women on HIV pre-exposure prophylaxis. AIDS care 2017. PMID: 29082776


  53. Bekker LG, Roux S, Sebastien E, Yola N, Amico KR, Hughes JP, Marzinke MA, Hendrix CW, Anderson PL, Elharrar V, Stirratt M, Rooney JF, Piwowar-Manning E, Eshleman SH, McKinstry L, Li M, Dye BJ, Grant RM. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. The lancet. HIV 2017. PMID: 28986029


  54. Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM. Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis. Journal of acquired immune deficiency syndromes (1999) 2017. PMID: 28639995


  55. Lal L, Audsley J, Murphy DA, Fairley CK, Stoove M, Roth N, Moore R, Tee BK, Puratmaja N, Anderson PL, Leslie D, Grant RM, De Wit J, Wright E. Medication adherence, condom use and sexually transmitted infections in Australian preexposure prophylaxis users. AIDS (London, England) 2017. PMID: 28700394


  56. Sivay MV, Li M, Piwowar-Manning E, Zhang Y, Hudelson SE, Marzinke MA, Amico RK, Redd A, Hendrix CW, Anderson PL, Bokoch K, Bekker LG, van Griensven F, Mannheimer S, Hughes JP, Grant R, Eshleman SH. Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT. Journal of acquired immune deficiency syndromes (1999) 2017. PMID: 28328548


  57. Markowitz M, Frank I, Grant RM, Mayer KH, Elion R, Goldstein D, Fisher C, Sobieszczyk ME, Gallant JE, Van Tieu H, Weinberg W, Margolis DA, Hudson KJ, Stancil BS, Ford SL, Patel P, Gould E, Rinehart AR, Smith KY, Spreen WR. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. The lancet. HIV 2017. PMID: 28546090


  58. Seidman DL, Weber S, Grant RM. Is pericoital or peri-insemination preexposure prophylaxis effective human immunodeficiency prevention for vaginal exposures? American journal of obstetrics and gynecology 2017. PMID: 28479285


  59. Amico KR, Wallace M, Bekker LG, Roux S, Atujuna M, Sebastian E, Dye BJ, Elharrar V, Grant RM. Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework. AIDS and behavior 2017. PMID: 27317411


  60. Truong HM, Mehrotra M, Montoya O, Lama JR, Guanira JV, Casapía M, Veloso VG, Buchbinder SP, Mayer KH, Chariyalertsak S, Schechter M, Bekker LG, Kallás EG, Grant RM. International Sexual Partnerships May Be Shaped by Sexual Histories and Socioeconomic Status. Sexually transmitted diseases 2017. PMID: 28407648


  61. Koechlin FM, Fonner VA, Dalglish SL, O'Reilly KR, Baggaley R, Grant RM, Rodolph M, Hodges-Mameletzis I, Kennedy CE. Values and Preferences on the Use of Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Multiple Populations: A Systematic Review of the Literature. AIDS and behavior 2017. PMID: 27900502


  62. Koester K, Amico RK, Gilmore H, Liu A, McMahan V, Mayer K, Hosek S, Grant R. Risk, safety and sex among male PrEP users: time for a new understanding. Culture, health & sexuality 2017. PMID: 28415911


  63. Glidden DV, Mayer K, Grant RM. Response to: A double-edged sword: does highly active antiretroviral therapy contribute to syphilis incidence by impairing immunity to Treponema pallidum? Sexually transmitted infections 2017. PMID: 28408646


  64. Koss CA, Bacchetti P, Hillier SL, Livant E, Horng H, Mgodi N, Mirembe BG, Gomez Feliciano K, Horn S, Liu AY, Glidden DV, Grant RM, Benet LZ, Louie A, van der Straten A, Chirenje ZM, Marrazzo JM, Gandhi M. Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations. AIDS research and human retroviruses 2017. PMID: 28253024


  65. Sevelius JM, Deutsch MB, Grant R. The future of PrEP among transgender women: the critical role of gender affirmation in research and clinical practices. Journal of the International AIDS Society 2016. PMID: 27760683


  66. Glidden DV, Anderson PL, Grant RM. Pharmacology supports on-demand PrEP. The lancet. HIV 2016. PMID: 27562738


  67. Gandhi M, Glidden DV, Mayer K, Schechter M, Buchbinder S, Grinsztejn B, Hosek S, Casapia M, Guanira J, Bekker LG, Louie A, Horng H, Benet LZ, Liu A, Grant RM. Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study. Volume 3 of Issue 11. The lancet. HIV 2016. PMID: 27658870


  68. Grant RM, Sevelius JM, Guanira JV, Aguilar JV, Chariyalertsak S, Deutsch MB. Transgender Women in Clinical Trials of Pre-Exposure Prophylaxis. Journal of acquired immune deficiency syndromes (1999) 2016. PMID: 27429187


  69. Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O'Reilly KR, Koechlin FM, Rodolph M, Hodges-Mameletzis I, Grant RM. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS (London, England) 2016. PMID: 27149090


  70. Defechereux PA, Mehrotra M, Liu AY, McMahan VM, Glidden DV, Mayer KH, Vargas L, Amico KR, Chodacki P, Fernandez T, Avelino-Silva VI, Burns D, Grant RM. Depression and Oral FTC/TDF Pre-exposure Prophylaxis (PrEP) Among Men and Transgender Women Who Have Sex With Men (MSM/TGW). AIDS and behavior 2016. PMID: 26078115


  71. Truong HM, Chen YH, Grasso M, Robertson T, Tao L, Fatch R, Curotto A, McFarland W, Grant RM, Reznick O, Raymond HF, Steward WT. HIV Serodisclosure and Sexual Behavior During International Travel. Sexually transmitted diseases 2016. PMID: 27322049


  72. Mehrotra ML, Glidden DV, McMahan V, Amico KR, Hosek S, Defechereux P, Mayer KH, Veloso VG, Bekker LG, Avelino-Silva VI, Schechter M, Grant RM. The Effect of Depressive Symptoms on Adherence to Daily Oral PrEP in Men who have Sex with Men and Transgender Women: A Marginal Structural Model Analysis of The iPrEx OLE Study. AIDS and behavior 2016. PMID: 27125241


  73. Kuebler PJ, Shaw BI, Leadabrand KS, Mehrotra ML, Grant RM, Kallás EG, Nixon DF. Brief Report: HIV-1 gp120 T-Cell Responses Correspond to Infection Outcomes in the Global iPrEx Chemoprophylaxis Trial. Journal of acquired immune deficiency syndromes (1999) 2016. PMID: 26674373


  74. Sevelius J, Deutsch MB, Glidden DV, Grant RM. PrEP adherence among trans women in Brazil-access needed for this key population - Authors' reply. The lancet. HIV 2016. PMID: 27126486


  75. Grant RM, Glidden DV. HIV moments and pre-exposure prophylaxis. Lancet (London, England) 2016. PMID: 27115970


  76. Yacoub R, Nadkarni GN, Weikum D, Konstantinidis I, Boueilh A, Grant RM, Mugwanya KK, Baeten JM, Wyatt CM. Elevations in Serum Creatinine With Tenofovir-Based HIV Pre-Exposure Prophylaxis: A Meta-Analysis of Randomized Placebo-Controlled Trials. Journal of acquired immune deficiency syndromes (1999) 2016. PMID: 26627105


  77. Solomon MM, Schechter M, Liu AY, McMahan VM, Guanira JV, Hance RJ, Chariyalertsak S, Mayer KH, Grant RM. The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B. Journal of acquired immune deficiency syndromes (1999) 2016. PMID: 26413853


  78. Glidden DV, Amico KR, Liu AY, Hosek SG, Anderson PL, Buchbinder SP, McMahan V, Mayer KH, David B, Schechter M, Grinsztejn B, Guanira J, Grant RM. Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016. PMID: 26797207


  79. Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, Chege W, Postle BS, Matheson T, Amico KR, Liegler T, Rawlings MK, Trainor N, Blue RW, Estrada Y, Coleman ME, Cardenas G, Feaster DJ, Grant R, Philip SS, Elion R, Buchbinder S, Kolber MA. Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services. Volume 176 of Issue 1. JAMA internal medicine 2016. PMID: 26571482


  80. Grant RM, Koester KA. What people want from sex and preexposure prophylaxis. Current opinion in HIV and AIDS 2016. PMID: 26569183


  81. Deutsch MB, Glidden DV, Sevelius J, Keatley J, McMahan V, Guanira J, Kallas EG, Chariyalertsak S, Grant RM. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. The lancet. HIV 2015. PMID: 26614965


  82. Koester KA, Grant RM. Editorial Commentary: Keeping Our Eyes on the Prize: No New HIV Infections With Increased Use of HIV Pre-exposure Prophylaxis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2015. PMID: 26334051


  83. Grant RM, Smith DK. Integrating Antiretroviral Strategies for Human Immunodeficiency Virus Prevention: Post- and Pre-Exposure Prophylaxis and Early Treatment. Open forum infectious diseases 2015. PMID: 26512356


  84. Kuebler PJ, Mehrotra ML, Shaw BI, Leadabrand KS, Milush JM, York VA, Defechereux P, Grant RM, Kallás EG, Nixon DF. Persistent HIV Type 1 Seronegative Status Is Associated With Lower CD8+ T-Cell Activation. The Journal of infectious diseases 2015. PMID: 26310308


  85. Truong HM, Pipkin S, O'Keefe KJ, Louie B, Liegler T, McFarland W, Grant RM, Bernstein K, Scheer S. Brief Report: Recent Infection, Sexually Transmitted Infections, and Transmission Clusters Frequently Observed Among Persons Newly Diagnosed With HIV in San Francisco. Journal of acquired immune deficiency syndromes (1999) 2015. PMID: 25967271


  86. Kuebler PJ, Mehrotra ML, McConnell JJ, Holditch SJ, Shaw BI, Tarosso LF, Leadabrand KS, Milush JM, York VA, Raposo RA, Cheng RG, Eriksson EM, McMahan V, Glidden DV, Shiboski S, Grant RM, Nixon DF, Kallás EG. Cellular immune correlates analysis of an HIV-1 preexposure prophylaxis trial. Proceedings of the National Academy of Sciences of the United States of America 2015. PMID: 26100867


  87. Weber S, Grant RM. Ending sexual HIV transmission: lessons learned from perinatal HIV. The Journal of the Association of Nurses in AIDS Care : JANAC 2015. PMID: 26096627


  88. Seidman D, Weber S, Aaron E, Cohan D, Grant R. The FACTS about women and pre-exposure prophylaxis. The lancet. HIV 2015. PMID: 26423194


  89. Koester KA, Liu A, Eden C, Amico KR, McMahan V, Goicochea P, Hosek S, Mayer KH, Grant RM. Acceptability of drug detection monitoring among participants in an open-label pre-exposure prophylaxis study. AIDS care 2015. PMID: 26001026


  90. Mulligan K, Glidden DV, Anderson PL, Liu A, McMahan V, Gonzales P, Ramirez-Cardich ME, Namwongprom S, Chodacki P, de Mendonca LM, Wang F, Lama JR, Chariyalertsak S, Guanira JV, Buchbinder S, Bekker LG, Schechter M, Veloso VG, Grant RM. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2015. PMID: 25908682


  91. Gandhi M, Glidden DV, Liu A, Anderson PL, Horng H, Defechereux P, Guanira JV, Grinsztejn B, Chariyalertsak S, Bekker LG, Grant RM. Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring. The Journal of infectious diseases 2015. PMID: 25895984


  92. Grant RM, Liegler T, Defechereux P, Kashuba AD, Taylor D, Abdel-Mohsen M, Deese J, Fransen K, De Baetselier I, Crucitti T, Bentley G, Agingu W, Ahmed K, Damme LV. Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women. AIDS (London, England) 2015. PMID: 25503265


  93. Grant RM, Liegler T. Weighing the risk of drug resistance with the benefits of HIV preexposure prophylaxis. The Journal of infectious diseases 2015. PMID: 25587019


  94. Gesner M, Maiti M, Grant R, Cavrois M. Fluorescence-linked Antigen Quantification (FLAQ) Assay for Fast Quantification of HIV-1 p24Gag. Bio-protocol 2014. PMID: 27525295


  95. Solomon MM, Nureña CR, Tanur JM, Montoya O, Grant RM, McConnell JJ. Transactional sex and prevalence of STIs: a cross-sectional study of MSM and transwomen screened for an HIV prevention trial. International journal of STD & AIDS 2014. PMID: 25520017


  96. Liu A, Glidden DV, Anderson PL, Amico KR, McMahan V, Mehrotra M, Lama JR, MacRae J, Hinojosa JC, Montoya O, Veloso VG, Schechter M, Kallas EG, Chariyalerstak S, Bekker LG, Mayer K, Buchbinder S, Grant R. Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study. Journal of acquired immune deficiency syndromes (1999) 2014. PMID: 25230290


  97. Guanira JV, Leigler T, Kallas E, Schechter M, Sharma U, Glidden D, Grant RM. Streamlining HIV testing for HIV preexposure prophylaxis. Journal of clinical microbiology 2014. PMID: 25378570


  98. Truong HM, Fatch R, Grasso M, Robertson T, Tao L, Chen YH, Curotto A, McFarland W, Grant RM, Reznick O, Raymond HF, Steward WT. Gay and bisexual men engage in fewer risky sexual behaviors while traveling internationally: a cross-sectional study in San Francisco. Sexually transmitted infections 2014. PMID: 25355773


  99. Solomon MM, Mayer KH, Glidden DV, Guanira JV, Grant RM. Reply to Boyd et al. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2014. PMID: 25323702


  100. Amico KR, Marcus JL, McMahan V, Liu A, Koester KA, Goicochea P, Anderson PL, Glidden D, Guanira J, Grant R. Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection. Journal of acquired immune deficiency syndromes (1999) 2014. PMID: 24853306


  101. Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, Hosek S, Mosquera C, Casapia M, Montoya O, Buchbinder S, Veloso VG, Mayer K, Chariyalertsak S, Bekker LG, Kallas EG, Schechter M, Guanira J, Bushman L, Burns DN, Rooney JF, Glidden DV. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. The Lancet. Infectious diseases 2014. PMID: 25065857


  102. Marrazzo JM, del Rio C, Holtgrave DR, Cohen MS, Kalichman SC, Mayer KH, Montaner JS, Wheeler DP, Grant RM, Grinsztejn B, Kumarasamy N, Shoptaw S, Walensky RP, Dabis F, Sugarman J, Benson CA. HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 2014. PMID: 25038358


  103. Solomon MM, Mayer KH, Glidden DV, Liu AY, McMahan VM, Guanira JV, Chariyalertsak S, Fernandez T, Grant RM. Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2014. PMID: 24928295


  104. Liegler T, Abdel-Mohsen M, Bentley LG, Atchison R, Schmidt T, Javier J, Mehrotra M, Eden C, Glidden DV, McMahan V, Anderson PL, Li P, Wong JK, Buchbinder S, Guanira JV, Grant RM. HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial. The Journal of infectious diseases 2014. PMID: 24740633


  105. Solomon MM, Lama JR, Glidden DV, Mulligan K, McMahan V, Liu AY, Guanira JV, Veloso VG, Mayer KH, Chariyalertsak S, Schechter M, Bekker LG, Kallás EG, Burns DN, Grant RM. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS (London, England) 2014. PMID: 24499951


  106. Marcus JL, Glidden DV, McMahan V, Lama JR, Mayer KH, Liu AY, Montoya-Herrera O, Casapia M, Hoagland B, Grant RM. Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men. PloS one 2014. PMID: 24637511


  107. Buchbinder SP, Glidden DV, Liu AY, McMahan V, Guanira JV, Mayer KH, Goicochea P, Grant RM. HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial. The Lancet. Infectious diseases 2014. PMID: 24613084


  108. Liu AY, Yang Q, Huang Y, Bacchetti P, Anderson PL, Jin C, Goggin K, Stojanovski K, Grant R, Buchbinder SP, Greenblatt RM, Gandhi M. Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP). PloS one 2014. PMID: 24421901


  109. Marcus JL, Glidden DV, Mayer KH, Liu AY, Buchbinder SP, Amico KR, McMahan V, Kallas EG, Montoya-Herrera O, Pilotto J, Grant RM. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis. PloS one 2013. PMID: 24367497


  110. Grohskopf LA, Chillag KL, Gvetadze R, Liu AY, Thompson M, Mayer KH, Collins BM, Pathak SR, O'hara B, Ackers ML, Rose CE, Grant RM, Paxton LA, Buchbinder SP. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. Journal of acquired immune deficiency syndromes (1999) 2013. PMID: 23466649


  111. Vallabhaneni S, McConnell JJ, Loeb L, Hartogensis W, Hecht FM, Grant RM, Pilcher CD. Changes in seroadaptive practices from before to after diagnosis of recent HIV infection among men who have sex with men. PloS one 2013. PMID: 23405145


  112. Gomez GB, Borquez A, Caceres CF, Segura ER, Grant RM, Garnett GP, Hallett TB. The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study. PLoS medicine 2012. PMID: 23055836


  113. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, McMahan V, Bushman LR, Casapía M, Montoya-Herrera O, Veloso VG, Mayer KH, Chariyalertsak S, Schechter M, Bekker LG, Kallás EG, Grant RM. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Science translational medicine 2012. PMID: 22972843


  114. R Amico K, McMahan V, Goicochea P, Vargas L, Marcus JL, Grant RM, Liu A. Supporting study product use and accuracy in self-report in the iPrEx study: next step counseling and neutral assessment. AIDS and behavior 2012. PMID: 22460228


  115. Truong HM, Kellogg TA, McFarland W, Louie B, Klausner JD, Philip SS, Grant RM. Sentinel surveillance of HIV-1 transmitted drug resistance, acute infection and recent infection. PloS one 2011. PMID: 22046237


  116. Jain V, Sucupira MC, Bacchetti P, Hartogensis W, Diaz RS, Kallas EG, Janini LM, Liegler T, Pilcher CD, Grant RM, Cortes R, Deeks SG, Hecht FM. Differential persistence of transmitted HIV-1 drug resistance mutation classes. The Journal of infectious diseases 2011. PMID: 21451005


  117. Jain V, Liegler T, Vittinghoff E, Hartogensis W, Bacchetti P, Poole L, Loeb L, Pilcher CD, Grant RM, Deeks SG, Hecht FM. Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009. PloS one 2010. PMID: 21170322


  118. Anderson PL, Kiser JJ, Gardner EM, Rower JE, Meditz A, Grant RM. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. The Journal of antimicrobial chemotherapy 2010. PMID: 21118913


  119. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallás EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. The New England journal of medicine 2010. PMID: 21091279


  120. Grant RM. Antiretroviral agents used by HIV-uninfected persons for prevention: pre- and postexposure prophylaxis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010. PMID: 20397962


  121. Hecht FM, Hartogensis W, Bragg L, Bacchetti P, Atchison R, Grant R, Barbour J, Deeks SG. HIV RNA level in early infection is predicted by viral load in the transmission source. AIDS (London, England) 2010. PMID: 20168202


  122. McConnell JJ, Bragg L, Shiboski S, Grant RM. Sexual seroadaptation: lessons for prevention and sex research from a cohort of HIV-positive men who have sex with men. PloS one 2010. PMID: 20098616


  123. Truong HM, Kellogg T, Schwarcz S, Delgado V, Grant RM, Louie B, Ngo H, McFarland W. Frequent international travel by men who have sex with men recently diagnosed with HIV-1: potential for transmission of primary HIV-1 drug resistance. Journal of travel medicine 2008. PMID: 19090802


  124. Willberg CB, McConnell JJ, Eriksson EM, Bragg LA, York VA, Liegler TJ, Hecht FM, Grant RM, Nixon DF. Immunity to HIV-1 is influenced by continued natural exposure to exogenous virus. PLoS pathogens 2008. PMID: 18949024


  125. Grant RM, Hamer D, Hope T, Johnston R, Lange J, Lederman MM, Lieberman J, Miller CJ, Moore JP, Mosier DE, Richman DD, Schooley RT, Springer MS, Veazey RS, Wainberg MA. Whither or wither microbicides? Science (New York, N.Y.) 2008. PMID: 18653884


  126. Bourara K, Liegler TJ, Grant RM. Target cell APOBEC3C can induce limited G-to-A mutation in HIV-1. PLoS pathogens 2007. PMID: 17967058


  127. Grant RM. Research in situ. Nature methods 2007. PMID: 17952085


  128. Abrams DI, Shade SB, Couey P, McCune JM, Lo J, Bacchetti P, Chang B, Epling L, Liegler T, Grant RM. Dehydroepiandrosterone (DHEA) effects on HIV replication and host immunity: a randomized placebo-controlled study. Volume 23 of Issue 1. AIDS research and human retroviruses 2007. PMID: 17263636


  129. Stopak KS, Chiu YL, Kropp J, Grant RM, Greene WC. Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. Volume 282 of Issue 6. The Journal of biological chemistry 2006. PMID: 17110377


  130. Truong HM, Grant RM, McFarland W, Kellogg T, Kent C, Louie B, Wong E, Klausner JD. Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance. AIDS (London, England) 2006. PMID: 17086059


  131. Barbour JD, Hecht FM, Little SJ, Markowitz M, Daar ES, Kelleher AD, Routy JP, Campbell TB, Rosenberg ES, Segal MR, Weidler J, Grant RM. Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity. AIDS (London, England) 2006. PMID: 17053362


  132. Zimmerman ES, Sherman MP, Blackett JL, Neidleman JA, Kreis C, Mundt P, Williams SA, Warmerdam M, Kahn J, Hecht FM, Grant RM, de Noronha CM, Weyrich AS, Greene WC, Planelles V. Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo. Volume 80 of Issue 21. Journal of virology 2006. PMID: 16956949


  133. Grant RM, Wainberg MA. Chemoprophylaxis of HIV infection: moving forward with caution. The Journal of infectious diseases 2006. PMID: 16960773


  134. Levy V, Grant RM. Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006. PMID: 16941375


  135. Liu AY, Grant RM, Buchbinder SP. Preexposure prophylaxis for HIV: unproven promise and potential pitfalls. JAMA 2006. PMID: 16905792


  136. Lama JR, Sanchez J, Suarez L, Caballero P, Laguna A, Sanchez JL, Whittington WL, Celum C, Grant RM. Linking HIV and antiretroviral drug resistance surveillance in Peru: a model for a third-generation HIV sentinel surveillance. Journal of acquired immune deficiency syndromes (1999) 2006. PMID: 16773026


  137. Sánchez MS, Grant RM, Porco TC, Getz WM. HIV drug-resistant strains as epidemiologic sentinels. Emerging infectious diseases 2006. PMID: 16494741


  138. Gange SJ, Schneider MF, Grant RM, Liegler T, French A, Young M, Anastos K, Wilson TE, Ponath C, Greenblatt R. Genotypic resistance and immunologic outcomes among HIV-1-infected women with viral failure. Journal of acquired immune deficiency syndromes (1999) 2006. PMID: 16340476


  139. Chin-Hong PV, Deeks SG, Liegler T, Hagos E, Krone MR, Grant RM, Martin JN. High-risk sexual behavior in adults with genotypically proven antiretroviral-resistant HIV infection. Journal of acquired immune deficiency syndromes (1999) 2005. PMID: 16280703


  140. Roland ME, Neilands TB, Krone MR, Katz MH, Franses K, Grant RM, Busch MP, Hecht FM, Shacklett BL, Kahn JO, Bamberger JD, Coates TJ, Chesney MA, Martin JN. Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005. PMID: 16231265


  141. Grant RM, Buchbinder S, Cates W, Clarke E, Coates T, Cohen MS, Delaney M, Flores G, Goicochea P, Gonsalves G, Harrington M, Lama JR, MacQueen KM, Moore JP, Peterson L, Sanchez J, Thompson M, Wainberg MA. AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science (New York, N.Y.) 2005. PMID: 16195446


  142. Hecht FM, Grant RM. Resistance testing in drug-naive HIV-infected patients: is it time? Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005. PMID: 16206109


  143. Deeks SG, Hoh R, Neilands TB, Liegler T, Aweeka F, Petropoulos CJ, Grant RM, Martin JN. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. The Journal of infectious diseases 2005. PMID: 16206068


  144. Neuenburg JK, Furlan S, Bacchetti P, Price RW, Grant RM. Enrichment of activated monocytes in cerebrospinal fluid during antiretroviral therapy. AIDS (London, England) 2005. PMID: 16103765


  145. Klausner JD, Grant RM, Kent CK. Detection of acute HIV infections. The New England journal of medicine 2005. PMID: 16093476


  146. Neuenburg JK, Cho TA, Nilsson A, Bredt BM, Hebert SJ, Grant RM, Price RW. T-cell activation and memory phenotypes in cerebrospinal fluid during HIV infection. Journal of acquired immune deficiency syndromes (1999) 2005. PMID: 15851909


  147. Barbour JD, Grant RM. The role of viral fitness in HIV pathogenesis. Current HIV/AIDS reports 2005. PMID: 16091246


  148. Papasavvas E, Kostman JR, Mounzer K, Grant RM, Gross R, Gallo C, Azzoni L, Foulkes A, Thiel B, Pistilli M, Mackiewicz A, Shull J, Montaner LJ. Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. PLoS medicine 2004. PMID: 15630469


  149. Sánchez MS, Grant RM, Porco TC, Gross KL, Getz WM. A decrease in drug resistance levels of the HIV epidemic can be bad news. Bulletin of mathematical biology 2004. PMID: 15893552


  150. Neuenburg JK, Sinclair E, Nilsson A, Kreis C, Bacchetti P, Price RW, Grant RM. HIV-producing T cells in cerebrospinal fluid. Volume 37 of Issue 2. Journal of acquired immune deficiency syndromes (1999) 2004. PMID: 15385730


  151. Barbour JD, Hecht FM, Wrin T, Liegler TJ, Ramstead CA, Busch MP, Segal MR, Petropoulos CJ, Grant RM. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS (London, England) 2004. PMID: 15280779


  152. Gross KL, Porco TC, Grant RM. HIV-1 superinfection and viral diversity. AIDS (London, England) 2004. PMID: 15238769


  153. Reyes-Sandoval A, Fitzgerald JC, Grant R, Roy S, Xiang ZQ, Li Y, Gao GP, Wilson JM, Ertl HC. Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes. Journal of virology 2004. PMID: 15220412


  154. Barbour JD, Hecht FM, Wrin T, Segal MR, Ramstead CA, Liegler TJ, Busch MP, Petropoulos CJ, Hellmann NS, Kahn JO, Grant RM. Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection. The Journal of infectious diseases 2004. PMID: 15216458


  155. Barbour JD, Grant RM. The Clinical Implications of Reduced Viral Fitness. Current infectious disease reports 2004. PMID: 15023278


  156. Segal MR, Barbour JD, Grant RM. Relating HIV-1 sequence variation to replication capacity via trees and forests. Statistical applications in genetics and molecular biology 2004. PMID: 16646798


  157. Angel JB, Hu YW, Kravcik S, Tsui R, Lee KH, Barbour J, Balaskas E, Branson BM, Delwart EL, Grant RM. Virological evaluation of the 'Ottawa case' indicates no evidence for HIV-1 superinfection. AIDS (London, England) 2004. PMID: 15075555


  158. Porco TC, Martin JN, Page-Shafer KA, Cheng A, Charlebois E, Grant RM, Osmond DH. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS (London, England) 2004. PMID: 15090833


  159. Tsui R, Herring BL, Barbour JD, Grant RM, Bacchetti P, Kral A, Edlin BR, Delwart EL. Human immunodeficiency virus type 1 superinfection was not detected following 215 years of injection drug user exposure. Journal of virology 2004. PMID: 14671091


  160. Papasavvas E, Grant RM, Sun J, Mackiewicz A, Pistilli M, Gallo C, Kostman JR, Mounzer K, Shull J, Montaner LJ. Lack of persistent drug-resistant mutations evaluated within and between treatment interruptions in chronically HIV-1-infected patients. AIDS (London, England) 2003. PMID: 14571185


  161. Bangsberg DR, Charlebois ED, Grant RM, Holodniy M, Deeks SG, Perry S, Conroy KN, Clark R, Guzman D, Zolopa A, Moss A. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS (London, England) 2003. PMID: 12960825


  162. Murphy EL, Grant RM, Kropp J, Oliveira A, Lee TH, Busch MP. Increased human T-lymphotropic virus type II proviral load following highly active retroviral therapy in HIV-coinfected patients. Journal of acquired immune deficiency syndromes (1999) 2003. PMID: 12902815


  163. Karlsson AC, Deeks SG, Barbour JD, Heiken BD, Younger SR, Hoh R, Lane M, Sällberg M, Ortiz GM, Demarest JF, Liegler T, Grant RM, Martin JN, Nixon DF. Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene. Journal of virology 2003. PMID: 12767994


  164. D'Aquila RT, Schapiro JM, Brun-Vézinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DD. Drug resistance mutations in HIV-1. Topics in HIV medicine : a publication of the International AIDS Society, USA 2003. PMID: 12837968


  165. Asmuth DM, Kalish LA, Laycock ME, Murphy EL, Mohr BA, Lee TH, Gallarda J, Giachetti C, Dollard SC, van der Horst CM, Grant RM, Busch MP. Absence of HBV and HCV, HTLV-I and -II, and human herpes virus-8 activation after allogeneic RBC transfusion in patients with advanced HIV-1 infection. Transfusion 2003. PMID: 12662277


  166. Grant RM, Kuritzkes DR, Johnson VA, Mellors JW, Sullivan JL, Swanstrom R, D'Aquila RT, Van Gorder M, Holodniy M, Lloyd RM, Reid C, Morgan GF, Winslow DL. Accuracy of the TRUGENE HIV-1 genotyping kit. Journal of clinical microbiology 2003. PMID: 12682149


  167. Kuritzkes DR, Grant RM, Feorino P, Griswold M, Hoover M, Young R, Day S, Lloyd RM, Reid C, Morgan GF, Winslow DL. Performance characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System. Journal of clinical microbiology 2003. PMID: 12682150


  168. Hayden MS, Palacios EH, Grant RM. Real-time quantitation of HIV-1 p24 and SIV p27 using fluorescence-linked antigen quantification assays. AIDS (London, England) 2003. PMID: 12598787


  169. Deeks SG, Grant RM, Wrin T, Paxinos EE, Liegler T, Hoh R, Martin JN, Petropoulos CJ. Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. AIDS (London, England) 2003. PMID: 12556690


  170. Schweighardt B, Ortiz GM, Grant RM, Wellons M, Miralles GD, Kostrikis LG, Bartlett JA, Nixon DF. Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. AIDS (London, England) 2002. PMID: 12441810


  171. D'Aquila RT, Schapiro JM, Brun-Vézinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DD. Drug Resistance Mutations in HIV-1. Topics in HIV medicine : a publication of the International AIDS Society, USA 2002. PMID: 12717052


  172. Barbour JD, Wrin T, Grant RM, Martin JN, Segal MR, Petropoulos CJ, Deeks SG. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. Journal of virology 2002. PMID: 12368352


  173. Neuenburg JK, Brodt HR, Herndier BG, Bickel M, Bacchetti P, Price RW, Grant RM, Schlote W. HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. Journal of acquired immune deficiency syndromes (1999) 2002. PMID: 12394795


  174. Sandberg JK, Fast NM, Palacios EH, Fennelly G, Dobroszycki J, Palumbo P, Wiznia A, Grant RM, Bhardwaj N, Rosenberg MG, Nixon DF. Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infection. Journal of virology 2002. PMID: 12097565


  175. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, Hellmann NS, Chesney M, Busch MP, Kahn JO. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002. PMID: 12095382


  176. Napolitano LA, Lo JC, Gotway MB, Mulligan K, Barbour JD, Schmidt D, Grant RM, Halvorsen RA, Schambelan M, McCune JM. Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone. AIDS (London, England) 2002. PMID: 12004268


  177. Keppler OT, Welte FJ, Ngo TA, Chin PS, Patton KS, Tsou CL, Abbey NW, Sharkey ME, Grant RM, You Y, Scarborough JD, Ellmeier W, Littman DR, Stevenson M, Charo IF, Herndier BG, Speck RF, Goldsmith MA. Progress toward a human CD4/CCR5 transgenic rat model for de novo infection by human immunodeficiency virus type 1. The Journal of experimental medicine 2002. PMID: 11901198


  178. Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS (London, England) 2002. PMID: 11807304


  179. Deeks SG, Hoh R, Grant RM, Wrin T, Barbour JD, Narvaez A, Cesar D, Abe K, Hanley MB, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK. CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. The Journal of infectious diseases 2002. PMID: 11807713


  180. Hassoba HM, Bzowej N, Berenguer M, Kim M, Zhou S, Phung Y, Grant R, Pessoa MG, Wright TL. Evolution of viral quasispecies in interferon-treated patients with chronic hepatitis C virus infection. Journal of hepatology 1999. PMID: 10551384


  181. Tan M, Klein R, Grant R, Ganem D, Engel J. Cloning and characterization of the RNA polymerase alpha-subunit operon of Chlamydia trachomatis. Journal of bacteriology 1993. PMID: 8226662


  182. Winkelstein W, Lyman DM, Padian N, Grant R, Samuel M, Wiley JA, Anderson RE, Lang W, Riggs J, Levy JA. Sexual practices and risk of infection by the human immunodeficiency virus. The San Francisco Men's Health Study. JAMA 1987. PMID: 3540327